--- title: "Customer Data: Use of Seraseq ctDNA Reference Samples to Validate Detection of Low Frequency Variants in a cfDNA-based NGS Lung Cancer Panel" description: At the recently-concluded 2018 AMP Meeting, researchers at the New York Presbyterian Hospital (NYPH) and Weill Cornell Medical Center (WCMC) presented a poster1 on the validation of an Oncomine™ cell-free DNA Lung Assay using ctDNA NGS standards developed by SeraCare (Seraseq® ctDNA v2 Reference Materials),2 for detecting low frequency somatic mutations at a range of DNA inputs to stress-test the NGS assay sensitivity. image: https://blog.seracare.com/hubfs/Imported_Blog_Media/customer-data-table-1.jpg --- ![logo](https://seracare.com/Content/themes/Skin_Default/images/lgc_logo.png) SeraCare is part of LGC Clinical Diagnostics - [Learn More](https://www.lgcclinicaldiagnostics.com/) [![SeraCare](https://blog.seracare.com/hs-fs/hubfs/0.%20Logos/SeraCare/SeraCare.png?width=400&name=SeraCare.png "SeraCare")](https://www.seracare.com) - [Home](https://blog.seracare.com/ngs) - [About](https://digital.seracare.com/about-blog) - [News and Events](http://www.seracare.com/NewsEvents/NewsCenter/tabid/354/Default.aspx) - [Contact](http://www.seracare.com/Contact/tabid/366/Default.aspx) ## [Diagnostic Precision](https://blog.seracare.com/) A SeraCare blog focused on precision medicine and advanced clinical diagnostics Choose your Article Focus | [All](https://blog.seracare.com/molecular-serology-blog) | [NGS](https://blog.seracare.com/topic/ngs) | [Molecular & Serology](https://blog.seracare.com/molecular-serology-blog/tag/molecular-serology) # Customer Data: Use of Seraseq ctDNA Reference Samples to Validate Detection of Low Frequency Variants in a cfDNA-based NGS Lung Cancer Panel Posted by [Omo Clement, PhD](https://blog.seracare.com/ngs/author/omo-clement-phd) on Feb 14, 2019 12:00:00 AM At the recently-concluded 2018 AMP Meeting, researchers at the New York Presbyterian Hospital (NYPH) and Weill Cornell Medical Center (WCMC) presented a poster1 on the validation of an Oncomine™ cell-free DNA Lung Assay using ctDNA NGS standards developed by SeraCare (**[Seraseq® ctDNA v2 Reference Materials](https://www.seracare.com/Controls---Reference-Materials-NGS-Somatic-Cancer-Liquid-Biopsy/)**),2 for detecting low frequency somatic mutations at a range of DNA inputs to stress-test the NGS assay sensitivity. In the study, low frequency variants (11 – see Table 1) in six lung cancer genes - EGFR, KRAS, BRAF, TP53, PIK3CA, and ERBB2 – covered in the Oncomine cfDNA Lung Cancer Assay were evaluated using plasma-based Seraseq ctDNA reference standards at **[AF0.1%](https://www.seracare.com/Seraseq-ctDNA-Reference-Material-v2-AF0125-0710-0207/)**, **[0.5%](https://www.seracare.com/Seraseq-ctDNA-Reference-Material-v2-AF05-0710-0205/)**, **[1%](https://www.seracare.com/Seraseq-ctDNA-Reference-Material-v2-AF1-0710-0204/)**, and **[2%](https://www.seracare.com/Seraseq-ctDNA-Reference-Material-v2-AF2-0710-0203/)**, and DNA inputs of 1ng, 5ng, 10ng, and 20ng. Testing was performed in triplicate. Sequencing on the Ion S5 platform yielded a mean coverage range between ~27,000x (1 ng) to ~96,000x (20 ng). The molecular coverage ranged between ~230x (1ng) to 2,855x (20ng), allowing accurate detection of low-frequency variants and reliable determination of limit of detection (LOD) cutoff values.   **Table 1:** List of cfDNA gene variants in the Seraseq ctDNA v2 reference samples2 concordant with Oncomine™ cfDNA Lung Cancer Assay.1 ![customer-data-table-1](https://blog.seracare.com/hs-fs/hubfs/Imported_Blog_Media/customer-data-table-1.jpg?width=355&name=customer-data-table-1.jpg) Figure 1 shows the correlation between expected and observed VAFs at 1 ng and 20 ng cfDNA inputs, suggesting that the assay is robust enough to call VAFs at low DNA inputs. However, the study found high CVs for VAFs at the lowest input of 1 ng (CV range of 44% to 138%) compared to a range of 18-51 at 10 or 20 ng DNA inputs. The study concludes that the Oncomine cfDNA Lung Assay, as validated with plasma-based contrived reference samples, is a sensitive cell-free DNA-based NGS panel for reliable and reproducible detection of specific low-frequency variants in cancer plasma samples. Careful validation and determination of LOD cutoff values in the context of DNA input is warranted.   ![customer-data-figure-1](https://blog.seracare.com/hs-fs/hubfs/Imported_Blog_Media/customer-data-figure-1.jpg?width=600&name=customer-data-figure-1.jpg) **Figure 1:** Performance of Oncomine™ Lung cfDNA Assay was measured across four VAF levels (**[0.1%](https://www.seracare.com/Seraseq-ctDNA-Reference-Material-v2-AF0125-0710-0207/)**, **[0.5%](https://www.seracare.com/Seraseq-ctDNA-Reference-Material-v2-AF05-0710-0205/)**, **[1%](https://www.seracare.com/Seraseq-ctDNA-Reference-Material-v2-AF1-0710-0204/)**, and **[2%](https://www.seracare.com/Seraseq-ctDNA-Reference-Material-v2-AF2-0710-0203/)**) of 11 targeted gene variants by input DNA. Graphical representation of the regression analysis for **(A)** 1 ng and **(B)** 20 ng input cfDNA is shown. There was an excellent concordance between the expected and observed VAFs using the quantitative multiplex reference standard. The correlation coefficients (*R*2) values were 0.90 and 0.99 for 1 ng and 20 ng input cfDNA, respectively.1 For more details about SeraCare’s ctDNA reference samples please visit **[our liquid biopsy portfolio](https://www.seracare.com/Controls---Reference-Materials-NGS-Somatic-Cancer-Liquid-Biopsy/)**. --- **Click below to download the scientific poster,** [**Assessment of the Oncomine™ cell-free DNA Lung Assay to Detect Low-Frequency Mutations using Reference Material**](https://www.seracare.com/resources-and-education/scientific-posters/assessment-oncomine-cfdna-lung-assay-detect-low-frequency-mutations-using-rm/) **References** 1. Lin Cong, Jordan Baum, Phyllis Ruggiero, John Sipley and Hanna Rennert, Department of Pathology, New York-Presbyterian Hospital and Weill Cornell Medicine, New York, NY; "**[Assessment of the Oncomine™ cell-free DNA Lung Assay to Detect Low-Frequency Mutations using Reference Material](https://www.seracare.com/resources-and-education/scientific-posters/assessment-oncomine-cfdna-lung-assay-detect-low-frequency-mutations-using-rm/)**," 2018 AMP Poster presentation (**[poster #: TT058](https://amp18.amp.org/AMP/assets/File/JMDPublishedAbstracts_November2018.pdf)**), San Antonio, TX, Nov 1-3, 2018. 1. **[Seraseq ctDNA v2 Reference Materials](https://www.seracare.com/Controls---Reference-Materials-NGS-Somatic-Cancer-Liquid-Biopsy/)**, manufactured by SeraCare Life Sciences Inc., 37 Birch Street, Milford, MA 01757. Topics: [AMP](https://blog.seracare.com/ngs/tag/amp), [SeraSeq](https://blog.seracare.com/ngs/tag/seraseq), [cfDNA](https://blog.seracare.com/ngs/tag/cfdna), [Lung Cancer](https://blog.seracare.com/ngs/tag/lung-cancer), [ctDNA](https://blog.seracare.com/ngs/tag/ctdna)     ### Subscribe Here!   [![New call-to-action](https://no-cache.hubspot.com/cta/default/20300467/538d26d7-6bf8-4208-9dad-6a783db06a0c.png)](https://cta-redirect.hubspot.com/cta/redirect/20300467/538d26d7-6bf8-4208-9dad-6a783db06a0c) ### Posts by Tag - [NGS (64)](https://blog.seracare.com/ngs/tag/ngs) - [reference materials (37)](https://blog.seracare.com/ngs/tag/reference-materials) - [clinical genomics (30)](https://blog.seracare.com/ngs/tag/clinical-genomics) - [ctDNA (29)](https://blog.seracare.com/ngs/tag/ctdna) - [cancer (24)](https://blog.seracare.com/ngs/tag/cancer) - [SeraSeq (16)](https://blog.seracare.com/ngs/tag/seraseq) - [cfDNA (14)](https://blog.seracare.com/ngs/tag/cfdna) - [NIPT (12)](https://blog.seracare.com/ngs/tag/nipt) - [RNA fusion (11)](https://blog.seracare.com/ngs/tag/rna-fusion) - [AACR (10)](https://blog.seracare.com/ngs/tag/aacr) - [AMP (10)](https://blog.seracare.com/ngs/tag/amp) - [liquid biopsy (10)](https://blog.seracare.com/ngs/tag/liquid-biopsy) - [FDA (7)](https://blog.seracare.com/ngs/tag/fda) - [ccfDNA (7)](https://blog.seracare.com/ngs/tag/ccfdna) - [LDT (6)](https://blog.seracare.com/ngs/tag/ldt) - [Assay Development (5)](https://blog.seracare.com/ngs/tag/assay-development) - [Reproductive Health (5)](https://blog.seracare.com/ngs/tag/reproductive-health) - [Accuplex (4)](https://blog.seracare.com/ngs/tag/accuplex) - [NTRK (4)](https://blog.seracare.com/ngs/tag/ntrk) - [Non-invasive Prenatal Testing (4)](https://blog.seracare.com/ngs/tag/non-invasive-prenatal-testing) - [QC Challenges (4)](https://blog.seracare.com/ngs/tag/qc-challenges) - [qc management (4)](https://blog.seracare.com/ngs/tag/qc-management) - [Lung Cancer (3)](https://blog.seracare.com/ngs/tag/lung-cancer) - [MRD (3)](https://blog.seracare.com/ngs/tag/mrd) - [New Reference Material (3)](https://blog.seracare.com/ngs/tag/new-reference-material) - [#Quality (2)](https://blog.seracare.com/ngs/tag/quality) - [EGFR (2)](https://blog.seracare.com/ngs/tag/egfr) - [Inherited Disease (2)](https://blog.seracare.com/ngs/tag/inherited-disease) - [Methylated DNA (2)](https://blog.seracare.com/ngs/tag/methylated-dna) - [Minimal Residual Disease (2)](https://blog.seracare.com/ngs/tag/minimal-residual-disease) - [Molecular Pathology (2)](https://blog.seracare.com/ngs/tag/molecular-pathology) - [PGT (2)](https://blog.seracare.com/ngs/tag/pgt) - [QC Management Software (2)](https://blog.seracare.com/ngs/tag/qc-management-software) - [TMB (2)](https://blog.seracare.com/ngs/tag/tmb) - [Women's health (2)](https://blog.seracare.com/ngs/tag/womens-health) - [myeloid cancer reference materials (2)](https://blog.seracare.com/ngs/tag/myeloid-cancer-reference-materials) - [ngs validation (2)](https://blog.seracare.com/ngs/tag/ngs-validation) - [trisomy (2)](https://blog.seracare.com/ngs/tag/trisomy) - [zika virus (2)](https://blog.seracare.com/ngs/tag/zika-virus) - [BioFidelity (1)](https://blog.seracare.com/ngs/tag/biofidelity) - [Breast Cancer (1)](https://blog.seracare.com/ngs/tag/breast-cancer) - [COVID-19 (1)](https://blog.seracare.com/ngs/tag/covid-19) - [Customer Testimonial (1)](https://blog.seracare.com/ngs/tag/customer-testimonial) - [Genomic Testing (1)](https://blog.seracare.com/ngs/tag/genomic-testing) - [HIV (1)](https://blog.seracare.com/ngs/tag/hiv) - [Immuno-Oncology (1)](https://blog.seracare.com/ngs/tag/immuno-oncology) - [PGS (1)](https://blog.seracare.com/ngs/tag/pgs) - [PGT-A (1)](https://blog.seracare.com/ngs/tag/pgt-a) - [Preimplantation genetic testing (1)](https://blog.seracare.com/ngs/tag/preimplantation-genetic-testing) - [QC Reporting (1)](https://blog.seracare.com/ngs/tag/qc-reporting) - [QC data management (1)](https://blog.seracare.com/ngs/tag/qc-data-management) - [Quality Management Systems (1)](https://blog.seracare.com/ngs/tag/quality-management-systems) - [SARS-CoV-2 (1)](https://blog.seracare.com/ngs/tag/sars-cov-2) - [bioinformatics (1)](https://blog.seracare.com/ngs/tag/bioinformatics) - [laboratory training (1)](https://blog.seracare.com/ngs/tag/laboratory-training) - [listeria (1)](https://blog.seracare.com/ngs/tag/listeria) - [methylated (1)](https://blog.seracare.com/ngs/tag/methylated) See all ### Recent Posts **About SeraCare** With over 30 years of experience as a leading partner to global in vitro diagnostics manufacturers and clinical testing laboratories, SeraCare’s clinical genomics technologies enable the promise of precision medicine by helping scientists and clinicians build and implement better clinical genomics assays. [Learn More](http://www.seracare.com/Company/WhoWeAre/tabid/335/Default.aspx)    - - - [Privacy Policy](http://www.seracare.com/PrivacyPolicy/tabid/211/Default.aspx)  |  [Legal Statement ](http://www.seracare.com/LegalStatement/tabid/212/Default.aspx) **Learn More** [Home](http://seracare.com/)  [About Us](http://seracare.com/Company/WhoWeAre/tabid/335/Default.aspx) [News and Events](http://www.seracare.com/NewsEvents/NewsCenter/tabid/354/Default.aspx)  [Blog](https://blog.seracare.com/)  [Contact](http://seracare.com/Contact/tabid/366/Default.aspx)  ![LGC+Marine-logo-FINAL-teal](https://blog.seracare.com/hs-fs/hubfs/1.%20Logos/LGC+Marine-logo-FINAL-teal.png?width=150&name=LGC+Marine-logo-FINAL-teal.png) 37 Birch Street Milford, MA 01757 [508-244-6400](tel:508-244-6400) l [800-676-1881](tel:800-676-1881) [info@seracare.com](mailto:info@seracare.com) ©2017 SeraCare Life Sciences, Inc. - [About SeraCare](http://www.seracare.com/Company/WhoWeAre/tabid/335/Default.aspx) - [Learn More](http://seracare.com/) - 37 Birch Street Milford, MA 01757 - Google Maps - 508-244-6400 - 508-634-3334 Fax - - - ![logo](https://blog.seracare.com/hubfs/logo.png "logo") 37 Birch Street Milford, MA 01757 508-244-6400 508-634-3334 Fax #### Products #### SeraCare #### Support & Resources - NGS & Digital PCR Tools - Controls & Reference Materials - Validation & Qualification Materials - Plasma & Serum Diluents & Derivatives - Cell Culture Reagents - KPL Antibodies & Conjugates - KPL Immunoassay Reagents & Kits - About Us - Careers - Press Releases - News Articles - Quality Systems - Terms & Conditions - Privacy Policy & Legal Statement - Register for an Account - Contact Us - Sign In - Resource Library - FAQs - Scientific Posters - White Papers - Videos ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Omo Clement, PhD", "url" : "https://blog.seracare.com/ngs/author/omo-clement-phd" }, "dateModified" : "2021-10-15T01:41:16.105Z", "datePublished" : "2019-02-14T05:00:00.000Z", "headline" : "Customer Data: Use of Seraseq ctDNA Reference Samples to Validate Detection of Low Frequency Variants in a cfDNA-based NGS Lung Cancer Panel", "image" : [ "https://blog.seracare.com/hubfs/Imported_Blog_Media/customer-data-table-1.jpg" ], "mainEntityOfPage" : { "@id" : "https://blog.seracare.com/ngs/customer-data-use-of-seraseq-ctdna-reference-samples-to-validate-detection-of-low-frequency-variants-in-a-cfdna-based-ngs-lung-cancer-panel", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.seracare.com/hubfs/0.%20Logos/SeraCare/SeraCare.png" }, "name" : "LGC Clinical Diagnostics" } } ```